inhibitor of DNA binding 2Genealiases: GIG8 · ID2A · ID2H · bHLHb26
Q-omics provides the consensus-scored ID2 profile across patient tissues and cancer cell-line models. ID2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ID2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ID2 RNA expression shows 19,062 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where ID2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ID2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ID2 survival associations across molecular data types. ID2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ID2 RNA expression–survival associations across cancer types. High ID2 expression shows unfavorable associations in ACC, but favorable associations in KIRC, THCA, SKCM, HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ID2 RNA expression.
This table summarizes ID2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ID2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ID2 shows lower tumor expression in KICH, LUAD, BLCA, LIHC and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher ID2 RNA expression in tumor versus normal tissue (log2 FC = +0.809, t-test p < 0.001).
This table shows molecular features associated with ID2 in patient tissues and cancer cell lines. In patient samples, ID2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ID2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
